sanofi-adr (SNY) Key Developments
Amgen Files Lawsuit Against Sanofi, Aventisub LLC and Regeneron Pharmaceuticals, Inc. for Patent Infringement
Oct 17 14
Amgen announced that it filed a lawsuit in the United States (U.S.) District Court of Delaware against Sanofi, Aventisub LLC, formerly doing business as Aventis Pharmaceuticals Inc. (collectively Sanofi), and Regeneron Pharmaceuticals, Inc. (Regeneron) for patent infringement of U.S. Patent Numbers 8,563,698, 8,829,165, and 8,859,741. These patents, which are owned by Amgen, describe and claim monoclonal antibodies to proprotein convertase subtilisin/kexin type 9 (PCSK9). By its complaint, Amgen seeks an injunction to prevent the infringing manufacture, use and sale of Sanofi and Regeneron's alirocumab, a monoclonal antibody targeting PCSK9. Sanofi and Regeneron recently announced that they have completed Phase 3 clinical trials on alirocumab and intend to pursue regulatory approval to market alirocumab in the U.S.
Selecta, JDRF and Sanofi Extend Collaboration to Develop Synthetic Vaccine Particle Immunotherapy for Type 1 Diabetes
Oct 15 14
Selecta Biosciences, Inc., and JDRF, announced that they have extended their joint research collaboration and attracted Sanofi as a partner in support of their program to develop a Synthetic Vaccine Particle (SVP) immunotherapy with the long-term goal to treat and potentially prevent the underlying cause of type 1 diabetes. This collaborative research program is aimed at accelerating the advancement of an SVP immunotherapy designed to reset the immune system and restore tolerance to substances (antigens) that cause the immune attacks on insulin-producing cells in the pancreas. As part of their collaboration, JDRF and Sanofi are co-financing the program with the aim of advancing the SVP product candidate to the clinic. This next phase of the SVP development program has been structured as a grant award to Selecta in order to test up to four antigens that may succeed in stopping the autoimmune response that destroys beta cells.
Sanofi's $7.9 Billion Portfolio Sale Reportedly In Limbo
Oct 3 14
Sanofi (ENXTPA:SAN)'s plan to sell or find partners for an $7.9 billion portfolio of established drugs is at a standstill amid disagreements among top managers as to how to move forward, Bloomberg reported citing people familiar with the matter. The assets have not been carved out into a separate business unit and management hasn’t decided what to keep or let go. Sanofi has no financial details to present to parties interested in the European portfolio. A spokesman for Sanofi declined to comment.
Sanofi Pasteur Introduces 4-Strain Influenza Vaccine in Canada
Oct 1 14
Sanofi Pasteur, the vaccines division of Sanofi, announced the launch of its 4-strain influenza vaccine (Fluzone(R) Quadrivalent) in Canada. This new vaccine was introduced in the United States in 2013 and is quickly becoming the new standard of care for the prevention of influenza. Licensed for use in individuals six months of age and older, Fluzone(R) Quadrivalent vaccine provides improved protection against influenza, and will be available in Canada starting this flu season. For almost four decades, seasonal flu vaccines have conferred protection against three strains: two A subtypes (A/H1N1 and A/H3N2) and one B type. However, the B type has since diverged into two distinct lineages (B/Victoria and B/Yamagata) which now co-circulate worldwide, and can lead to mismatches between the predicted and actual circulating B strains. Influenza B is often responsible for flu epidemics, which occur every two to four years, and the associated illnesses, deaths, and high costs of hospitalization. In recent years, influenza B viruses have represented up to 53% of annually circulating strains in Canada. Age groups at higher risk include youth (<=19 years old) and the elderly (>=65 years old), which, in 2012-2013, represented 40% and 35% of hospitalizations associated with influenza B, respectively. The new 4-strain vaccine represents the logical next step in the evolution of influenza immunization.
Apollo Hospitals and Sanofi Announce Collaboration to Provide an Integrated Care Program in India for People with Diabetes
Sep 30 14
Apollo Hospitals and Sanofi announced their decision to collaborate on the expansion of Apollo Sugar Clinics, which provide integrated diabetes care programs in India. Through this collaboration, Apollo and Sanofi plan to leverage their respective expertise in diabetes to provide patients with access to comprehensive educational resources, treatment and care programs that can help patients better manage their diabetes. The first wave of this collaboration will focus on the establishment of 50 Apollo Sugar Clinics. In line with concentrated efforts towards controlling the burgeoning diabetes epidemic - both globally and in India, the Apollo Sugar Clinics endeavour is to make diabetes 'disease-free' by offering easy access to an integrated diabetes care solution within a clinical infrastructure, which promotes early detection and treatment of diabetes and associated complications, strengthened by lifestyle management and behaviour change programs. All these together can lead to better compliance with necessary treatments and potentially lead to better patient outcomes.